Satisfaction and Quality of Life in Patients With a Diagnosis of Non Valvular Atrial Fibrillation Who Take Rivaroxaban for Stroke Prevention
Phase of Trial: Phase III
Latest Information Update: 23 Jan 2017
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Atrial fibrillation; Embolism and thrombosis; Stroke
- Focus Therapeutic Use
- Acronyms SAFARI
- Sponsors Bayer
- 28 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Oct 2014 According to the ClinicalTrials.gov, status changed from recruiting to active, no longer recruiting.
- 03 May 2014 Planned End Date changed from 1 Jun 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov.